Oramed Pharmaceuticals Inc (ORMP)vsRegeneron Pharmaceuticals Inc (REGN)
ORMP
Oramed Pharmaceuticals Inc
$3.50
+2.34%
HEALTHCARE · Cap: $141.46M
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 717045% more annual revenue ($14.34B vs $2.00M). REGN leads profitability with a 31.4% profit margin vs 21.9%. ORMP trades at a lower P/E of 3.5x. REGN earns a higher WallStSmart Score of 58/100 (C).
ORMP
Hold49
out of 100
Grade: D+
REGN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+93.1%
Fair Value
$46.80
Current Price
$3.50
$43.30 discount
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Earnings expanding 40.9% YoY
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Areas to Watch
Smaller company, higher risk/reward
Revenue declined 100.0%
Negative free cash flow — burning cash
Operating margin of -6.5%
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : ORMP
The strongest argument for ORMP centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 21.9% and operating margin at -6.5%.
Bull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bear Case : ORMP
The primary concerns for ORMP are Market Cap, Revenue Growth, Free Cash Flow.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ORMP profiles as a declining stock while REGN is a value play — different risk/reward profiles.
ORMP carries more volatility with a beta of 1.28 — expect wider price swings.
REGN is growing revenue faster at 2.5% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (58/100 vs 49/100), backed by strong 31.4% margins. ORMP offers better value entry with a 93.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Oramed Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for the administration of polypeptides. The company is headquartered in New York, New York.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?